Johnson & Johnson (JNJ) Q2 Earnings Report: Key Takeaways
Johnson & Johnson surpassed Wall Street expectations for its second-quarter financial results, reporting $25.31 billion in total sales—a 6.6% increase year-over-year. Driven by strong demand for immunology drug Tremfya and oncology treatment Darzalex, the healthcare giant raised its full-year guidance, now projecting mid-point sales of $101.1 billion and adjusted earnings of $11.68 per share. Pharmaceutical … Read more